CCTG Phase III Award presented to the CHU MAC.30 clinical trials team

First row seated: Marie-Claude Lépine, Christne Desbiens, Isabelle Ouelletn Second row: Kristine Langlois, Manon Desgagné, Fanie Bourgault, Marie-Helene Levesque, Eric Vachon, Nathalie Vaillancourt, Eve Desgagnés, Emile Groleau, Judith-Elise Marcoux, Justine Pringalle, Francois Martel, Marjolaine Drolet, Caroline Pagé 

CCTG was honoured to recognize the team work and dedication of the MAC.30 clinical trials team from the Centre des maladies du sein du CHU de Québec–Université Laval with the Phase III Team Award. The team was presented the award for their impressive performance in trial accrual, local activation timelines, compliance metrics and team performance.

"By receiving the 2026 Phase III Team Award for the MAC.30 trial, our team at the Centre des maladies du sein du CHU de Québec–Université Laval celebrates its leadership in breast cancer clinical research. This recognition highlights the dedication and excellence of our nurses, physicians, research coordinators, data specialists, and professionals who work every day to improve care for women with breast cancer. Each patient who participates helps move science forward, and this award acknowledges both the scientific rigor of our team and the courage of the women who choose to contribute to research. A heartfelt thank you to CCTG for this distinction and especially to our patients and their families for their trust and collaboration."